Skip to main content
Equibles

RDY · Dr Reddys Laboratories Ltd

Track RDY — free

Use RDY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RDY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$12.25 +0.00 (+0.00%) At close · Oct 2
Rebalance outlook locked
Market Cap
$10.20B
Shares
832.99M
Volume · Oct 2 3.8M Avg daily vol (3M) 2.87M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$12.25 Open$12.29 Day$12.08–12.31 52W close$11.38–15.38 Avg vol 30d2.9M Short int29.0M · 3.5% float · 9.0d Short vol38% Last earningsSep 30, 2025 DataJan 2020–Oct 2026

Up next

Q2 2026 earnings call transcript
call held Sep 30, 2025

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+3.2%
Year over year
Operating margin
15.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.0%
Year over year · more shares
Price change (1Y)
-13.7%
Trailing year
Short interest
3.5%
Latest settlement · 9.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Moderate
Market backdrop VIX 15.3 · calm Equity put/call 0.58
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg −8%
below
Price vs 50-day avg +1%
above
RSI (14) 50
neutral
MACD trend Positive
52-week position 22%
mid-range
Momentum
relative strength
Very Weak
1-month return +2%
trailing
6-month return −8%
trailing
YTD return −13%
this year
Relative strength −20%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $12 › 200d $13 — 200d above 50d
Institutional flow Accumulating
2 of 240 funds reported for Sep 30 · net +82 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.48% of float · ▲ +21.2% MoM · 9.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
240 holders — mid 3-yr range
Squeeze score 67
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Moderate
Volatility 27%
annualized · 1-yr
Max drawdown −26%
past year
ATR 2.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Jun 30, 2020
Effective tax rate · full year 25% – 27%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−8% Bearish
Price vs 50-day avg
+1% Bullish
RSI (14)
50 Neutral
MACD trend
Positive Bullish
52-week position
22% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $12 › 200d $13 — 200d above 50d
Institutional flow Accumulating
2 of 240 funds reported for Sep 30 · net +82 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.48% of float · ▲ +21.2% MoM · 9.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
240 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $11 Now $12 · 22% Range high $15
vs 200-day avg -8% vs 50-day avg +1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RDY
Dr Reddys Laboratories Ltd
this stock
$10.20B -12.7% — — 3.5%
TAK
Takeda Pharmaceutical Co Ltd
 $60.23B +14.6% — — 0.1%
GALDY
Galderma Group AG/ADR
 $46.00B -6.5% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
 $45.67B +26.7% +4.3% 64.3 2.7%
HLN
Haleon plc
 $40.72B -13.0% — — 0.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
240
% held
15.1%
Reported
2 of 240
Top holder
Robeco Institutional Asse…
Held Float
View
Held by Funds
Fund positions
60
View
Short & Settlement
Short Interest Rising
Shares short
29.0M
Days to cover
9.0d
Change
+5.1M sh
View
Short Volume
Short vol %
38%
As of
Oct 2, 2026
Short Total
View
Fails to Deliver
FTD shares
303.0K
Value
$3.6M
As of
Sep 14, 2026
View
Off-Exchange
Off-exchange %
40.5%
Week of
Aug 24, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Sep 22, 2026
This year
89
View
Proposed Sales
Value
$5.4M
Shares
65.5K
Filed
Jul 29, 2024
View
Earnings & Events
Webcasts
Last webcast
Sep 30, 2025
View

Performance

5D 20D 120D MTD YTD
RDY +0.0% +1.8% -7.7% -2.9% -12.8%
SPY -0.2% -0.5% +12.2% +0.9% +12.9%
vs SPY +0.2% +2.3% -19.9% -3.9% -25.6%
Key facts CIK 1135951 CUSIP 256135203 13F (30d) 6 filings 6 filers Visit website Investor relations